Disc Medicine Inc. research snapshot
IRON AI stock analysis currently reads Disc Medicine as a clinical-stage hematology biotech whose near-term value depends on the Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria (EPP). The analysis is not a certain price prediction. At the August 4, 2026 cutoff, the latest verified close was $76.31, market capitalization was about $2.91 billion, and the main question is whether APOLLO topline data in Q4 2026 supports a successful Complete Response Letter response and a potential traditional approval by mid-2027. This is informational research and not investment advice.
Current price
$76.31
Market cap
$2.91 billion
AI score
46 / 100
Rating
Neutral, pre-revenue hematology biotech with a defined CRL response path
Trend status
Upper half of the 50-day range, below the 52-week high, short interest rising
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Disc Medicine is a pre-revenue clinical-stage biotech focused on hematologic disease, with bitopertin as its lead candidate. It has no approved products, but the July 30, 2026 update shows a strengthening pipeline and a clear regulatory path rather than a single unmanaged binary event. | Medium |
| Moat | The potential moat comes from first-in-class biology in heme biosynthesis and iron homeostasis, orphan drug protections, the EU Orphan Drug Designation for selcodebart, and specialized hematology expertise. The moat stays unproven until regulatory approval and commercial execution are demonstrated. | Low |
| Management | CEO John Quisel (JD, PhD) leads an experienced biotech team. Recent insider activity is a monitoring flag: insiders sold about $7.6 million of stock over the past three months, including a $2.47 million sale by the CEO in July 2026. | Medium |
| Financial trend | Zero revenue with a Q2 2026 net loss of $59.5 million, slightly better than the $55.2 million loss in Q2 2025 and better than consensus. Cash, equivalents, and marketable securities were $717.7 million as of June 30, 2026, with runway into 2029. | High |
| Valuation | At roughly $2.91 billion market cap with a price-to-book ratio of 3.91 and book value of $19.52 per share, the stock prices in bitopertin approval and meaningful commercial revenue. Traditional valuation metrics (PE, FCF yield) are not applicable for a pre-revenue biotech. | Low |
| Technical trend | IRON closed at $76.31 on August 3, 2026, in the upper half of its 50-day range of $65.80 to $80.06 and below its 52-week high of $99.50. TradeSmith rated the stock in its Green zone over the past month, while short interest rose to 19.85% of float. | Medium |
| Risk level | Very high. Key risks are APOLLO failing or the CRL response being rejected, pipeline setbacks, securities class action investigation, high and rising short interest, and the long timeline to an FDA decision in mid-2027. | High |
| AI confidence | Medium confidence for filing-confirmed financial data and pipeline facts. Low confidence for valuation estimates and probability-weighted outcomes, which depend on the binary APOLLO readout and regulatory review. | Medium data confidence |
| Investment certainty | Low certainty. The gap between a best case and a worst case remains wide until the APOLLO topline data in Q4 2026, and no analysis can narrow that gap before the readout. | Low |
IRON AI stock forecast
The IRON AI stock forecast uses scenario ranges around the $76.31 cutoff price. It does not claim that AI can predict a specific future price. The bullish case requires a positive APOLLO topline readout and a successful CRL response path. The base case assumes positive data but a slower FDA review or a narrow label. The bearish case assumes APOLLO failure or a rejected CRL response that leaves the stock trading near cash value.
$110 to $140
More likely if APOLLO topline data in Q4 2026 is positive, the FDA accepts the CRL response and grants a traditional approval by mid-2027, selcodebart Phase 2 data stays strong, and DISC-3405 advances through Phase 2 in polycythemia vera and Phase 1b in sickle cell disease.
$65 to $95
More likely if APOLLO is positive but the FDA requires a narrow label or a longer review, pipeline data is mixed, and the stock trades within its 50-day range while analysts hold average targets near $99 to $104.
$20 to $40
More likely if APOLLO misses endpoints, the CRL response is rejected, selcodebart or DISC-3405 data disappoints, or negative news accelerates the sell-off. Cash of roughly $19 per share provides a partial floor but not full downside protection.
IRON AI technical analysis
IRON AI technical analysis starts from the $76.31 close on August 3, 2026 used for this August 4 static page. Public quote sources showed the stock in the upper half of its 50-day range, above its 52-week low of $40.00 and below its 52-week high of $99.50, with short interest of 19.85% of float suggesting potential for sharp moves. Because this page does not fetch request-time market data, traders should confirm levels on a live chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $76.31 | Latest verified close as of the August 4, 2026 data cutoff, down 0.90% on the August 3 session. |
| Near support | $65.80 | The low end of the 50-day trading range of $65.80 to $80.06, a zone where buyers have defended the recent trend. |
| Secondary support | $55 to $60 | The area the stock tested around mid-February 2026 before the recovery toward the 50-day band. |
| Near resistance | $80.06 | The high end of the 50-day trading range, a level the stock needs to clear to resume a stronger uptrend. |
| 52-week high | $99.50 | The 52-week high. A sustained break above the 50-day range with volume would be needed to approach it again. |
| 52-week low | $40.00 | The 52-week low. A close below it would challenge the entire recovery thesis. |
| Trend band | $65.80 to $80.06 (50-day range) | The stock closed in the upper half of this band, consistent with a constructive near-term trend. |
| Momentum | Green zone on TradeSmith | TradeSmith placed IRON in its Green zone over the past month, indicating a healthy uptrend with normal pullbacks. |
| Volume | 294,006 shares on Aug 3 | Below the average volume of 441,504 shares (MarketBeat), suggesting reduced conviction at current levels. |
| Volatility | High, typical for clinical-stage biotech | Binary catalysts such as the Q4 2026 APOLLO readout can move the stock 15% to 30% or more in either direction. |
| Invalidation | Close below $65.80, then $40 | A close below the 50-day range low would break the near-term trend. A break below $40 (52-week low) would invalidate the recovery thesis. |
IRON AI trading strategy
The IRON AI trading strategy is a rules-based framework, not personalized advice. For a catalyst-driven biotech like IRON, position sizing and catalyst timing matter more than technical patterns.
Map the expected Q4 2026 APOLLO topline readout and the mid-2027 FDA decision timeline, then build a position with a defined timeline and maximum loss. Risk only capital you can afford to lose entirely.
Define a maximum loss of 20% to 30% before entering. If the APOLLO readout or FDA review slips, reassess the position based on the new timeline.
If IRON pulls back toward the $65 to $70 area without negative news and the APOLLO catalyst remains intact, a mean-reversion entry could offer a better risk-reward. Confirm with volume stabilization near support.
Do not add to a losing position. If the stock breaks below the 50-day range low on negative news, the near-term thesis is damaged.
Track APOLLO topline data timing (expected Q4 2026), the FDA CRL response review, selcodebart end-of-Phase 2 interaction, DISC-3405 initial data, quarterly cash burn, financing announcements, and analyst target changes.
Reduce or exit if APOLLO misses endpoints, the CRL response is rejected, the company announces a dilutive financing, or insider selling accelerates significantly.
Investment research summary
Disc Medicine develops treatments for serious hematologic diseases by targeting heme biosynthesis and iron homeostasis. Its lead candidate, bitopertin, treats erythropoietic protoporphyria (EPP), a rare genetic condition causing severe light sensitivity. The pipeline also targets anemia of myelofibrosis (selcodebart) and polycythemia vera and sickle cell disease (DISC-3405).
The potential moat is based on first-in-class mechanisms in porphyria and anemia, orphan drug protections, the EU Orphan Drug Designation for selcodebart, and specialized heme-regulation expertise. The actual moat is unproven until regulatory approval and commercial adoption are achieved.
The thesis can fail if APOLLO misses endpoints, the FDA rejects the CRL response, selcodebart or DISC-3405 data disappoints, cash burn exceeds the runway into 2029, the securities class action investigation escalates, or short covering turns into extended selling pressure.
CEO John Quisel (JD, PhD) leads a team with relevant regulatory and development experience. Insider selling continues: insiders sold about $7.6 million over the past three months, including a $2.47 million CEO sale in July 2026, which merits close monitoring for alignment.
Disc Medicine operates in hematology, a field with strong unmet need, orphan drug pricing premiums, and active FDA and investor interest. Rare disease therapies can command premium pricing, but the path from approval to profitability is long and capital-intensive.
At about $2.91 billion market cap and zero revenue, IRON is priced for bitopertin approval and successful commercialization. Book value is $19.52 per share and cash is roughly $19 per share, so a bear case without approval would pull the stock toward a fraction of the current price.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| IRON price | $76.31 close on August 3, 2026, down 0.90% | Google Finance and MarketBeat quote snapshots | August 4, 2026 |
| Market capitalization | $2.91 billion, verified as $76.31 x 38.16 million shares (0.07% deviation) | financial_rigor.py market cap verification and MarketBeat; Google Finance lists $2.93 billion on 38.39 million shares | August 4, 2026 |
| Shares outstanding | 38.16 million shares (MarketBeat) / 38.39 million (Google Finance) | Google Finance and MarketBeat | August 4, 2026 |
| EPS (TTM) | -$6.58 (MarketBeat) / -$6.57 (Google Finance) | Google Finance and MarketBeat | August 4, 2026 |
| 52-week range | $40.00 to $99.50 | Google Finance and MarketBeat | August 4, 2026 |
| Q2 2026 net loss | -$59.5 million, EPS -$1.54 (beat consensus of -$1.71), reported July 30, 2026 | Disc Medicine Q2 2026 press release (GlobeNewswire) | August 4, 2026 |
| Cash position | $717.7 million in cash, equivalents, and marketable securities as of June 30, 2026, with runway into 2029 | Disc Medicine Q2 2026 press release | August 4, 2026 |
| Analyst consensus | Moderate Buy, 11 analysts, average price target $104.44 (MarketBeat); Google Finance shows 10 analysts with an average of $98.86 | MarketBeat analyst ratings and Google Finance | August 4, 2026 |
| Short interest | 19.85% of float, 10.79 days to cover, up 14.57% month over month (July 15, 2026 report) | MarketBeat short interest data | August 4, 2026 |
| Insider and institutional ownership | Insider 3.76%, institutional 83.70%; insiders sold about $7.6 million in the past three months | MarketBeat ownership data | August 4, 2026 |
| Book value and P/B | Book value $19.52 per share, price-to-book ratio 3.91 | MarketBeat | August 4, 2026 |
| Beta | 1.00 (MarketBeat) / 0.97 (Google Finance) | Google Finance and MarketBeat | August 4, 2026 |
This IRON AI stock analysis is an informational tool for research and education only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of August 4, 2026 and can be wrong. Clinical-stage biotech investing carries a high risk of total capital loss.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
